Detalhe da pesquisa
1.
Dose Fractionation of Moxifloxacin for Treatment of Tuberculosis: Impact of Dosing Interval and Elimination Half-Life on Microbial Kill and Resistance Suppression.
Antimicrob Agents Chemother
; 65(4)2021 03 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33468465
2.
Polymyxin B Pharmacodynamics in the Hollow-Fiber Infection Model: What You See May Not Be What You Get.
Antimicrob Agents Chemother
; 65(8): e0185320, 2021 07 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34097487
3.
The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy Regimens.
Antimicrob Agents Chemother
; 65(2)2021 01 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33199386
4.
Emergence of Resistance to Ceftazidime-Avibactam in a Pseudomonas aeruginosa Isolate Producing Derepressed blaPDC in a Hollow-Fiber Infection Model.
Antimicrob Agents Chemother
; 65(6)2021 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33782013
5.
Building Optimal Three-Drug Combination Chemotherapy Regimens.
Antimicrob Agents Chemother
; 64(11)2020 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32900682
6.
Developing New Drugs for Mycobacterium tuberculosis Therapy: What Information Do We Get from Preclinical Animal Models?
Antimicrob Agents Chemother
; 64(12)2020 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32958720
7.
Pharmacodynamics of Ceftazidime plus Avibactam against KPC-2-Bearing Isolates of Klebsiella pneumoniae in a Hollow Fiber Infection Model.
Antimicrob Agents Chemother
; 63(8)2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31160285
8.
Determination of the Dynamically Linked Indices of Fosfomycin for Pseudomonas aeruginosa in the Hollow Fiber Infection Model.
Antimicrob Agents Chemother
; 62(6)2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29581114
9.
The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model.
Antimicrob Agents Chemother
; 62(12)2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30249700
10.
Activity of Moxifloxacin against Mycobacterium tuberculosis in Acid Phase and Nonreplicative-Persister Phenotype Phase in a Hollow-Fiber Infection Model.
Antimicrob Agents Chemother
; 62(12)2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30249693
11.
Linezolid Kills Acid-Phase and Nonreplicative-Persister-Phase Mycobacterium tuberculosis in a Hollow-Fiber Infection Model.
Antimicrob Agents Chemother
; 62(8)2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29866864
12.
Evaluation of Combination Drug Therapy for Treatment of Antibiotic-Resistant Inhalation Anthrax in a Murine Model.
Antimicrob Agents Chemother
; 61(9)2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28696235
13.
Natural History of Francisella tularensis in Aerosol-Challenged BALB/c Mice.
Antimicrob Agents Chemother
; 60(3): 1834-40, 2016 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-26824958
14.
From lead optimization to NDA approval for a new antimicrobial: Use of pre-clinical effect models and pharmacokinetic/pharmacodynamic mathematical modeling.
Bioorg Med Chem
; 24(24): 6401-6408, 2016 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27612961
15.
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1.
Antimicrob Agents Chemother
; 60(3): 1183-93, 2015 Dec 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26711759
16.
Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2.
Antimicrob Agents Chemother
; 60(3): 1194-201, 2015 Dec 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26711766
17.
Pharmacodynamic evaluation of the activities of six parenteral vancomycin products available in the United States.
Antimicrob Agents Chemother
; 59(1): 622-32, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25385113
18.
Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.
Antimicrob Agents Chemother
; 59(9): 5602-10, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26124169
19.
Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate.
Clin Infect Dis
; 58 Suppl 1: S28-34, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24343829
20.
Quantifying the matrix of relationships between reduced vancomycin susceptibility phenotypes and outcomes among patients with MRSA bloodstream infections treated with vancomycin .
J Antimicrob Chemother
; 69(9): 2547-55, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24840624